Accessibility Menu
 
Arrow-Thin-Down
S&P 500
7,230.12
+0.3%
+21.11
Arrow-Thin-Down
DJI
49,499.27
-0.3%
-152.87
Arrow-Thin-Down
NASDAQ
25,114.44
+0.9%
+222.13
Arrow-Thin-Down
Bitcoin
$78,194.00
-0.1%
-$109.33
Arrow-Thin-Down
AAPL
$280.19
+3.3%
+$8.84
Arrow-Thin-Down
AMZN
$268.36
+1.2%
+$3.30
Arrow-Thin-Down
GOOG
$382.96
+0.3%
+$1.02
Arrow-Thin-Down
META
$608.57
-0.5%
-$3.34
Arrow-Thin-Down
MSFT
$414.40
+1.6%
+$6.62
Arrow-Thin-Down
NVDA
$198.61
-0.5%
-$0.96
Arrow-Thin-Down
TSLA
$390.97
+2.4%
+$9.34
Most Active StocksDaily Stock GainersDaily Stock Losers
Medite Cancer Diagnostics logo

Medite Cancer Diagnostics

(OTC) MDIT

Current Price$0.00
Market Cap$8,600
Since IPO (1998)-100%
5 Year-100%
1 Year+9,900%
1 Month+0%

Medite Cancer Diagnostics Financials at a Glance

Market Cap

$8,600

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-16.62 (Low)

Price

$0.00

Volume

5

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.01

MDIT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Medite Cancer Diagnostics

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Headquarters

Orlando, FL 32832, US

MDIT Financials

Key Financial Metrics (TTM)

Gross Margin

-2%

Operating Margin

-95%

Net Income Margin

-100%

Return on Equity

0%

Return on Capital

-53%

Return on Assets

-43%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$8.60K

Shares Outstanding

86.20M

Volume

5

Avg. Volume

0.603

Financials (TTM)

Gross Profit

$131.00K

Operating Income

$6.48M

EBITDA

$6.19M

Operating Cash Flow

$2.58M

Capital Expenditure

$134.00K

Free Cash Flow

$2.72M

Cash & ST Invst.

$490.00K

Total Debt

$5.39M

Medite Cancer Diagnostics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

$8.60K

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Net Cash

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RCARRenovaCare, Inc.
$0.00+0.00%
ASFXAmerican Scientific Resources, Incorporated
$0.00+0.00%
FIORFFiore Cannabis Ltd.
$0.00+0.00%
LOWLFLowell Farms Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$99.62+0.05%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.07+0.05%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.70+0.01%
SOFISoFi Technologies
$16.43+0.02%

Questions About MDIT

What is the current price of Medite Cancer Diagnostics?

Medite Cancer Diagnostics is trading at $0.00 per share.

What is the 52-week range for Medite Cancer Diagnostics?

Over the past 52 weeks, Medite Cancer Diagnostics has traded between $0.00 and $0.01.

How much debt does Medite Cancer Diagnostics have?

Medite Cancer Diagnostics total debt is unavailable.

How much cash does Medite Cancer Diagnostics have on hand?

Medite Cancer Diagnostics does not have cash on hand data available.

What is Medite Cancer Diagnostics’s dividend yield?

Medite Cancer Diagnostics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services